| Literature DB >> 32947840 |
Paola Astolfi1, Michela Pisani1, Elisabetta Giorgini2, Barbara Rossi3, Alessandro Damin4, Francesco Vita1, Oriano Francescangeli1, Lorenzo Luciani5, Rossana Galassi5.
Abstract
Gold(I) phosphane compounds have recently attracted a renewed interest as potential new protagonists inEntities:
Keywords: DOPE; drug delivery; gold compounds; lyotropic cubic and hexagonal mesophases; monoolein; phytantriol
Year: 2020 PMID: 32947840 PMCID: PMC7558674 DOI: 10.3390/nano10091851
Source DB: PubMed Journal: Nanomaterials (Basel) ISSN: 2079-4991 Impact factor: 5.076
Figure 1Chemical structures of glyceryl monooleate (GMO), phytantriol (PHYT), 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE), ((triphenylphosphine)-gold(I)-(4,5-dichloroimidazolyl-1H-1yl) (C-I) and ((triphenylphosphine)-gold(I)-(4,5-dicyanoimidazolyl-1H-1yl) (C-II).
Figure 2Small-angle X-ray scattering (SAXS) synchrotron profiles for (A) GMO, (B) PHYT and (C) DOPE empty and loaded with C-I and C-II compounds.
Phase structure, lattice parameters and diameter of aqueous channels of GMO, PHYT and DOPE empty and loaded.
| Sample | Phase | Lattice Parameter (nm) | Average Diameter of the Core Channel (nm) |
|---|---|---|---|
| GMO |
| 13.24 | 4.49 |
| GMO/C-I |
| 6.09 | 2.49 |
| GMO/C-II |
| 6.13 | 2.53 |
| PHYT |
| 6.54 | 2.31 |
| PHYT/C-I |
| 4.90 | 2.10 |
| PHYT/C-II |
| 5.01 | 2.21 |
| DOPE |
| 7.31 | 2.90 |
| DOPE/C-I |
| 7.03 | 2.62 |
| DOPE/C-II |
| 7.25 | 2.84 |
Figure 3Raman spectra acquired on the pristine drugs C-I (a) and C-II (d) and theoretical Raman activity computed for the molecules of C-I (b) and C-II (e) in the spectral region 1100–1800 cm−1; UV resonant Raman (UVRR) spectra acquired on C-I (c) and C-II (f) dissolved in methanol.
Figure 4UVRR spectra acquired on pristine drug C-I (a) and on the complex formed by C-I with (b) GMO, (c) PHYT and (d) DOPE; on pristine drug C-II (e) and on the complex formed by C-II with (f) GMO, (g) PHYT and (h) DOPE. The spectra (b–d,f–h) have been subtracted from the lipid matrices signals. Insets: enlargement of the wavenumber region 1650–1530 cm−1 for the spectra of C-I and C-I complex with DOPE (left) and spectra of C-II and C-II complex with DOPE (right).
Figure 5IR spectra of C-I (collected (a) and computed (b); 1800–600 cm−1 spectral range), and C-II (collected (c) and computed (d); 2400–600 cm−1 spectral range) drugs. The position (in terms of wavenumbers, cm−1) of the most significant peaks observed in C-I and C-II is shown.
Figure 6IR spectra of: (a) C-I pristine and loaded in the complexes C-I/PHYT, C-I/GMO, and C-I/DOPE (1800–900 cm−1 spectral range); (b) C-II pristine and loaded in the complexes C-II/PHYT, C-II/GMO, and C-II/DOPE (2400–900 cm−1 spectral range). The IR spectra of the lipid matrices PHYT, GMO, and DOPE are also reported for clarity. The position (in terms of wavenumbers, cm−1) of the most significant peaks observed in C-I and C-II is shown.